JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On March8, 2018, Juniper Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results for the three-month and twelve-month periods ended December31, 2017, entitled “Juniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating Results” (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for the purposes of Section18 of the United State Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of Section18. Furthermore, the information shall not be deemed incorporated by reference into any registration statement or any other filing under the United States Securities Act of 1933, as amended, except as shall be expressly set forth by specific references in such filings.
| Item 2.02 | Shareholder Director Nominations |
On January31, 2018, the Company announced that it had retained Rothschild as its independent financial advisor and was exploring strategic alternatives.In light of the foregoing, the Company has elected to delay its 2018 annual meeting until the second half of 2018.Accordingly, the Company has extended the deadline for making shareholder proposals, including director nominations. Proposals of shareholders intended to be presented at the 2018 annual meeting must be received at the Company’s offices not later than July30, 2018 and satisfy the requirements set forth in the Company’s amended and restated by-laws.Proposals intended for inclusion in the company’s proxy statement for the annual meeting must also satisfy the requirements for shareholder proposals as set forth in Rule 14a-8 under the Securities Exchange Act of 1934, as amended.
Item 2.02. Financial Statements and Exhibits
(d) Exhibits
EXHIBIT INDEX
|
Exhibit No. |
Description |
| 99.1 | Press Release dated March8, 2018, entitled “Juniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating Results”, furnished herewith. |
JUNIPER PHARMACEUTICALS INC ExhibitEX-99.1 2 d535640dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Juniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating Results Full Year CRINONE® Revenues Increased 20% and Juniper Pharma Services (JPS) Revenues Increased 32% Year-over-Year Ended 2017 Cash Flow Positive; Company Expects Trend to Continue in 2018 Conference Call at 8:30 a.m. EST Today BOSTON,…To view the full exhibit click here
About JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP)
Juniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE. The product segment also includes the royalty stream the Company receives from Allergan for CRINONE sales in the United States, as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services for the its customers, as well as characterizing and developing pharmaceutical product candidates for its internal programs, and managing the preclinical and clinical manufacturing of COL-1077 and its intra-vaginal ring (IVR). Its product and product development programs include CRINONE 8%, COL-1077, JNP-0101, JNP-0101 and JNP-0301.
